No Data
No Data
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $80
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
Crispr Therapeutics AG (CRSP) Receives a Buy From Bank of America Securities
Leerink Partners Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $60
Analysts' Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Applied Therapeutics (APLT)
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 25% Price Increase Over Last Week